52 related articles for article (PubMed ID: 26155827)
1. Time, timing, and the treatment of diffuse large B-cell lymphoma.
Gerds AT; Sekeres MA
Leuk Lymphoma; 2016 Feb; 57(2):247-248. PubMed ID: 26155827
[No Abstract] [Full Text] [Related]
2. Rethinking Prognosis and Therapy for Follicular Lymphoma.
Jacobson CA; Freedman AS
J Clin Oncol; 2015 Aug; 33(23):2489-91. PubMed ID: 26169620
[No Abstract] [Full Text] [Related]
3. Recent advances in antibody-based therapies for Hodgkin Lymphoma.
Peggs KS
Br J Haematol; 2015 Oct; 171(2):171-178. PubMed ID: 26184792
[TBL] [Abstract][Full Text] [Related]
4. Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network.
Damaj G; Ivanoff S; Coso D; Ysaebert L; Choquet S; Houillier C; Parcelier A; Abarah W; Marjanovic Z; Gressin R; Garidi R; Diouf M; Gac AC; Dupuis J; Troussard X; Morschhauseur F; Ghesquières H; Soussain C;
Haematologica; 2015 Sep; 100(9):1199-206. PubMed ID: 26185174
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibition in T-cell lymphoma: a path(way) forward.
Moskowitz AJ; Horwitz SM
Blood; 2015 Jul; 126(3):284-6. PubMed ID: 26185115
[TBL] [Abstract][Full Text] [Related]
6. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
[TBL] [Abstract][Full Text] [Related]
7. MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.
Lu TX; Fan L; Wang L; Wu JZ; Miao KR; Liang JH; Gong QX; Wang Z; Young KH; Xu W; Zhang ZH; Li JY
Oncotarget; 2015 Jul; 6(21):18374-88. PubMed ID: 26158410
[TBL] [Abstract][Full Text] [Related]
8. Caution in the Use of Immunohistochemistry for Determination of Cell of Origin in Diffuse Large B-Cell Lymphoma.
Gleeson M; Hawkes EA; Cunningham D; Jack A; Linch D
J Clin Oncol; 2015 Oct; 33(28):3215-6. PubMed ID: 26261254
[No Abstract] [Full Text] [Related]
9. Cell of origin of transformed follicular lymphoma.
Kridel R; Mottok A; Farinha P; Ben-Neriah S; Ennishi D; Zheng Y; Chavez EA; Shulha HP; Tan K; Chan FC; Boyle M; Meissner B; Telenius A; Sehn LH; Marra MA; Shah SP; Steidl C; Connors JM; Scott DW; Gascoyne RD
Blood; 2015 Oct; 126(18):2118-27. PubMed ID: 26307535
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin: Seeing the Forest and the Trees.
Younes A
J Clin Oncol; 2015 Sep; 33(26):2835-6. PubMed ID: 26261249
[No Abstract] [Full Text] [Related]
11. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM
Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343
[TBL] [Abstract][Full Text] [Related]
12. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.
Deng L; Xu-Monette ZY; Loghavi S; Manyam GC; Xia Y; Visco C; Huh J; Zhang L; Zhai Q; Wang Y; Qiu L; Dybkær K; Chiu A; Perry AM; Zhang S; Tzankov A; Rao H; Abramson J; Sohani AR; Xu M; Hsi ED; Zhu J; Ponzoni M; Wang S; Li L; Zhang M; Ferreri AJ; Parsons BM; Li Y; Piris MA; Medeiros LJ; Young KH
Leukemia; 2016 Feb; 30(2):361-72. PubMed ID: 26308769
[TBL] [Abstract][Full Text] [Related]
13. Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: A US population-based analysis.
Giri S; Bhatt VR; Pathak R; Bociek RG; Vose JM; Armitage JO
Am J Hematol; 2015 Nov; 90(11):1052-4. PubMed ID: 26270899
[TBL] [Abstract][Full Text] [Related]
14. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
15. Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma.
Yano S; Mori T; Kanda Y; Kato J; Nakaseko C; Fujisawa S; Tomita N; Sakai R; Shono K; Saitoh T; Aotsuka N; Kobayashi N; Saito T; Takahashi S; Kanamori H; Okamoto S;
Bone Marrow Transplant; 2015 Oct; 50(10):1299-305. PubMed ID: 26168068
[TBL] [Abstract][Full Text] [Related]
16. Combined-Modality Therapy for Early-Stage Diffuse Large B-Cell Lymphoma: Knowing When to Quit.
Longo DL
J Clin Oncol; 2015 Nov; 33(32):3684-5. PubMed ID: 26282641
[No Abstract] [Full Text] [Related]
17. Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy?
Vargo JA; Gill BS; Balasubramani GK; Beriwal S
J Clin Oncol; 2015 Nov; 33(32):3710-7. PubMed ID: 26261253
[TBL] [Abstract][Full Text] [Related]
18. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis.
Song CG; Huang JJ; Li YJ; Xia Y; Wang Y; Bi XW; Jiang WQ; Huang HQ; Lin TY; Li ZM
PLoS One; 2015; 10(7):e0133973. PubMed ID: 26222726
[TBL] [Abstract][Full Text] [Related]
20. PET-Directed Therapy for Hodgkin's Lymphoma.
Bishop G
N Engl J Med; 2015 Jul; 373(4):392. PubMed ID: 26200988
[No Abstract] [Full Text] [Related]
[Next] [New Search]
